TY - JOUR
T1 - MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases
AU - Aranda, Juan F.
AU - Madrigal-Matute, Julio
AU - Rotllan, Noemi
AU - Fernández-Hernando, Carlos
N1 - Funding Information:
This work was supported by grants from the National Institutes of Health ( R01HL107953 and R01HL106063 to C.F.-H.). N.R. is supported by the Ministerio de Educación (Programa Nacional de Movilidad de Recursos Humanos del Plan Nacional de I-D+i 2008–2011). Figures were produced using Servier Medical Art (www.servier.com). C.F.-H has patents on the use of miRNA-33 inhibitors.
PY - 2013
Y1 - 2013
N2 - The regulation of the metabolism of cholesterol has been one of the most studied biological processes since its first isolation from gallstones in 1784. High levels of plasma low-density lipoprotein (LDL) cholesterol and reduced levels of plasma high-density lipoprotein (HDL) cholesterol are widely recognized as major risk factors of cardiovascular disease. An imbalance in the production of reactive oxygen species can oxidize LDL particles, increasing the levels of the highly proatherogenic oxidized LDL. Furthermore, under pathological scenarios, numerous molecules can function as pro-oxidants, such as iron or (high levels of) glucose. In addition to the classical mechanisms regulating lipid homeostasis, recent studies have demonstrated the important role of microRNAs (miRNAs) as regulators of lipoprotein metabolism, oxidative derivatives of lipoprotein, and redox balance. Here, we summarize recent findings in the field, highlighting the contributions of some miRNAs to lipid- and oxidative-associated pathologies. We also discuss how therapeutic intervention of miRNAs may be a promising strategy to decrease LDL, increase HDL, and ameliorate lipid- and oxidative-related disorders, including atherosclerosis, nonalcoholic fatty liver disease, and metabolic syndrome.
AB - The regulation of the metabolism of cholesterol has been one of the most studied biological processes since its first isolation from gallstones in 1784. High levels of plasma low-density lipoprotein (LDL) cholesterol and reduced levels of plasma high-density lipoprotein (HDL) cholesterol are widely recognized as major risk factors of cardiovascular disease. An imbalance in the production of reactive oxygen species can oxidize LDL particles, increasing the levels of the highly proatherogenic oxidized LDL. Furthermore, under pathological scenarios, numerous molecules can function as pro-oxidants, such as iron or (high levels of) glucose. In addition to the classical mechanisms regulating lipid homeostasis, recent studies have demonstrated the important role of microRNAs (miRNAs) as regulators of lipoprotein metabolism, oxidative derivatives of lipoprotein, and redox balance. Here, we summarize recent findings in the field, highlighting the contributions of some miRNAs to lipid- and oxidative-associated pathologies. We also discuss how therapeutic intervention of miRNAs may be a promising strategy to decrease LDL, increase HDL, and ameliorate lipid- and oxidative-related disorders, including atherosclerosis, nonalcoholic fatty liver disease, and metabolic syndrome.
KW - Atherosclerosis
KW - Free radicals
KW - Lipid metabolism
KW - MiRNAs
UR - http://www.scopus.com/inward/record.url?scp=84885184011&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885184011&partnerID=8YFLogxK
U2 - 10.1016/j.freeradbiomed.2013.07.014
DO - 10.1016/j.freeradbiomed.2013.07.014
M3 - Review article
C2 - 23871755
AN - SCOPUS:84885184011
SN - 0891-5849
VL - 64
SP - 31
EP - 39
JO - Free Radical Biology and Medicine
JF - Free Radical Biology and Medicine
ER -